Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
Howe
Charles L
CL
Bergstrom
Rachel A
RA
Horazdovsky
Bruce F
BF
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D007279:Injections, Subcutaneous; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage / Q000493:pharmacokinetics*
D007334:Insulin-Like Growth Factor I